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Introduction
The current recommendation of the
NHS Diabetic Eye Screening Pro-
gramme is for all people with diabetes
aged 12 years or over to be screened
with digital retinal photographs each
year until they have evidence of sight
threatening diabetic retinopathy, which
is deﬁned by the referable criteria used
by the English NHS Diabetic Eye
Screening Programme. The referable
criteria are the presence of features of
maculopathy (M1), preproliferative
(R2) or proliferative retinopathy (R3)
or a combination of these features, as
deﬁned in the methods section. Pres-
ence of any evidence of referable dia-
betic retinopathy (RDR) results in
referral to the Hospital Eye Service.
Patients with only mild background
retinopathy continue to be managed
in the same way as those with no evi-
dence of diabetic retinopathy and
receive annual screening.
Here, we compare the risk of pro-
gression to RDR in those with mild
background retinopathy in one eye, in
both eyes and those with no DR. We
also speciﬁcally compared the risk of
progression to maculopathy (M1) and
proliferative retinopathy (R3) and a
combination of preproliferative (R2)
and proliferative retinopathy (R3) in
the same groups.
Materials and Methods
The Gloucestershire Diabetic Eye
Screening Service delivers retinal
screening through a mobile screening
programme in 85 primary care prac-
tices. Two ﬁeld 45 digital retinal
images (macular and disc centred) are
graded in a central ofﬁce by an experi-
enced quality assured team.
The criteria used for grading in the
Gloucestershire Diabetic Eye Screen-
ing Programme and the relationship
to the Early Treatment Diabetic Reti-
nopathy Study (ETDRS) severity scale
(ETDRS 1991) are described below:
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ABSTRACT.
Purpose: The Gloucestershire Diabetic Eye Screening Programme offers annual
digital photographic screening for diabetic retinopathy to a countywide population
of people with diabetes. This study was designed to investigate progression of dia-
betic retinopathy in this programme of the English NHS Diabetic Eye Screening
Programme.
Methods: Mydriatic digital retinal photographs of people with diabetes screened
on at least 2 occasions between 2005 and 2010 were graded and included in this
study if the classiﬁcation at ﬁrst screening was no DR (R0), background DR in
one (R1a) or both eyes (R1b). Times to detection of referable diabetic retinopathy
(RDR) comprising maculopathy (M1), preproliferative (R2) or proliferative reti-
nopathy (R3) were analysed using survival models.
Results: Data were available on 19 044 patients, 56% men, age at screening 66
(57–74) years (median, 25th, 75th centile). A total of 8.3% of those with R1a and
28.2% of those with R1b progressed to any RDR, hazard ratios 2.9 [2.5–3.3] and
11.3 [10.0–12.8]. Similarly 7.1% and 0.11% of those with R1a progressed to M1
and R3, hazard ratios 2.7 [2.3–3.2] and 1.6 [0.5–5.0], compared to 21.8% and
1.07% of those with R1b, hazard ratio 9.1 [7.8–10.4] and 15.0 [7.1–31.5].
Conclusions: The risk of progression is signiﬁcantly higher for those with back-
ground DR in both eyes than those with background retinopathy in only one or in
neither eye.
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R0 level identiﬁes no detected dia-
betic retinopathy (equivalent to ET-
DRS level 10).
R1 level (mild NPDR or back-
ground DR) identiﬁes a minimum of
at least the presence of one microan-
eurysm and ⁄or retinal haemorrhage,
equivalent to ETDRS levels 20–35.
R1a deﬁned the presence of these fea-
tures in only one eye and R1b the
presence in both eyes.
R2 level (moderate to severe NPDR
or preproliferative DR) identiﬁes the
presence of multiple deep, round or
blot haemorrhages and ⁄or deﬁnite int-
raretinal microvascular abnormality
(IRMA) and ⁄or venous beading
and ⁄or reduplication, equivalent to
levels 43–53 on the ETDRS scale.
R3 level (proliferative DR) indicates
the presence of proliferative diabetic
retinopathy (including ﬁbrous prolifer-
ation), equivalent to a minimum of
ETDRS level 61.
M1 (maculopathy) identiﬁes the
presence of 2-dimensional photo-
graphic markers of diabetic maculopa-
thy, speciﬁcally exudate within 1 disc
diameter (DD) of the centre of the
fovea, circinate or group of exudates
within the macula or any microaneu-
rysm or haemorrhage within 1DD of
the centre of the fovea but only if asso-
ciated with a best VA of worse than 0.3
logMAR (equivalent to Snellen 6 ⁄12).
M0 describes the absence of any
M1 features.
Patients were categorized into groups
on the basis of the presence of retinopa-
thy in neither, one or both eyes at each
of the two baseline screening episodes.
Patients with unassessable images, with
any evidence of previous laser treatment
or with features of sight-threatening
diabetic retinopathy (STDR) at either
baseline screening event were excluded.
Sight-threatening diabetic retinopathy
was deﬁned by the presence of any R2
(moderate to severe NPDR), R3 (prolif-
erative DR) or M1 (maculopathy) in
either eye.
We reviewed all patients with assess-
able images of both eyes from at least
two screening episodes between January
2005 and December 2010. We included
those who at the ﬁrst (index) screening
had no retinopathy or only mild
background retinopathy in one or both
eyes. They were followed up until refer-
able retinopathy was detected or until no
more screening episodes were available.
Life table survival plots were
derived using Kaplan–Meier estimates.
Hazard ratios were calculated using
Cox Proportional Hazards models.
Because the data were interval cen-
sored (screening being carried out at
approximately yearly intervals), the
models were ﬁtted using semi-closed
intervals in PROC PHREG in SAS.
All data were analysed using SAS 9.1
(SAS Institute Inc., Cary, NC, USA).
Results
Data were available on 19 044
patients (see Table 1) and 10 705
(56.2%) were men. The median age at
ﬁrst screening (years) was 66 (57–74)
The median LogMAR visual acuity in
the better eye was 0.06 (0.00–0.20)
The median time from ﬁrst screening
to rescreening (months) was 13.5 (12–
15) The median follow-up (months)
was 41 (24–53).
A total of 8.3% of those with R1a
and 28.2% of those with R1b pro-
gressed to RDR, hazard ratios 2.9
(2.5–3.3) and 11.3 (10.0–12.8). 7.1%
of those with R1a progressed to M1,
hazard ratios 2.7 (2.3–3.1), compared
to 21.8% with R1b, hazard ratio 9.1
(7.9–10.4). 2.56% of those with R1a
progressed to R2 or R3, hazard ratio
4.6 (3.4–6.2), compared to 15.8% of
those with R1b, hazard ratio 30.7
Table 1. The inﬂuence of baseline screening result on subsequent screening referral.
N = 19 044 Median (25th, 75th centile)
Male 10705 (56.2%)
Age at index screening (years) 66 (57–74)
LogMAR visual acuity in better eye 0.06 (0.00–0.20)
Time from index screening to rescreening (months) 13.5 (12–15)
Follow-up (months) 41 (24–53)
Number progressing to referable DR (RDR),
maculopathy (M1), preproliferative (R2) or prolifera-
tive DR (R3), or to proliferative DR (R3 alone).
Hazard ratios for the development of each referable category
No in
group RDR* M1 R2 or R3 R3 RDR M1 R2 or R3 R3
No DR 12491 399 (3.19%) 361 (2.89%) 74 (0.59%) 9 (0.07%) 1 1 1 1
R1 in
1 eye (R1a)
3744 312 (8.33%) 267 (7.13%) 96 (2.56%) 4 (0.11%) 2.9 (2.5–3.3) 2.6 (2.3–3.1) 4.6 (3.4–6.2) 1.6 (0.5–5.0)
R1 in both
eyes (R1b)
2809 792 (28.2%) 611 (21.8%) 446 (15.8%) 30 (1.07%) 11.3 (10.0–12.8) 9.1 (7.9–10.4) 30.7 (24.0–39.3) 14.9 (7.1–31.5)
No DR R1 in 1 eye (R1a) R1 in both eyes (R1b)
No in group 12 491 3744 2809
Male (%) 6928 (55.5%) 2172 (58.0%) 1606 (57.2%)
Age at index screening (years) 66 (57–74) 67 (58–75) 66 (56–75)
LogMAR visual acuity in better eye 0.06 (0.0–0.2) 0.06 (0–0.2) 0.06 (0–0.2)
Time from index screening to rescreening
(months)
13.5 (12.0–15.2) 13.4 (12.0–15.2) 13.7 (12.1–15.4)
Follow-up (months) 46 (26–53) 41 (24–53) 39 (24–52)
* As individual patients could develop a combination of M1, R2 or R3, the sum of these columns will not be the same as the total RDR.
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(24.0–39.3). 0.11% of those with R1a
progressed to R3, 1.6 (0.5–5.0), com-
pared to 1.07% of those with R1b,
hazard ratio 15.0 (7.1–31.5).
The rates of progression are shown
in Figs 1–4, which demonstrate that
the risk of progression is signiﬁcantly
higher (p < 0.001) for those with
background DR in both eyes than
those with background retinopathy in
one only or in neither eye.
An analysis was carried out by age
group (patients partitioned into
10-year age groups). Within each age
group, the risks observed overall were
seen, with the HR for progression in
group 1b (R1 in both eyes) being
highly signiﬁcant in all groups
(p < 0.001) and because of the smaller
numbers signiﬁcant for group 1a (R1
in 1 eye) p < 0.01 in all age groups.
Discussion
In 1986, Kohner (Kohner & Sleight-
holm 1986) demonstrated that there is
a relationship between microaneurysm
count and severity of diabetic retinop-
athy. The United Kingdom Prospec-
tive Diabetes Study (UKPDS,
Aldington et al. 1995) and the Wis-
consin Epidemiological Study (Klein
et al. 1995) both demonstrated the
relationship between retinal microan-
eurysm count and progression of dia-
betic retinopathy.
A later report (Kohner et al. 1999)
from UKPDS reported that the pres-
ence of microaneurysms alone, and
also the number of microaneurysms
had a high predictive value for wors-
ening retinopathy at 3, 6, 9 and
12 years after entry into the study.
In 2001, Kohner (Kohner et al.
2001) reported the relationship in
UKPDS between the severity of reti-
nopathy and progression to photoco-
agulation in patients with Type 2
diabetes mellitus in the UKPDS.
Nunes (Nunes et al. 2009) reported
a relationship between high microan-
eurysm formation rate on colour fun-
dus photographs and DR progression
to clinically signiﬁcant macular
oedema in type 2 diabetic patients
with non-proliferative DR.
More recent studies have shown
that the rate of progression of diabetic
retinopathy has slowed in more recent
time periods. This may reﬂect earlier
diagnosis of Type 2 diabetes,
improved control of hyperglycaemia
and treatment of hypertension in Type
1 and Type 2 diabetes. Differences in
baseline characteristics, age (UKPDS
recruitment stopped at 65), ethnicity
and particularly in the prevalence and
severity of retinopathy, could also
have contributed to these differences.
The current study included 19 044
people with diabetes and was designed
to test the inﬂuence of baseline DR and
to report demographic characteristics in
relation to progression to referable or
proliferative diabetic retinopathy from
at least two screening episodes between
January 2005 and December 2010. It is
likely that confounding factors are pres-
ent, those with background DR are
likely to have higher levels of HbA1c
and to have had diabetes for longer.
However, in this study, we have not
included these data as they are not
routinely available in screening pro-
grammes, certainly not in the English
programme. Because this screening pro-
gramme continues to screen patients
once they have been referred to an oph-
thalmologist the problem of competing
risks is minimized. Progression from R2
ro R3 is unlikely to be affected by refer-
ral as it is not routine to treat R2 and
advice to maintain good glucose control
is unlikely to have a large effect in the
next 12 or 24 months.
This study has shown that the risk
of progression to referable DR is sig-
Fig. 1. Time to proliferative DR (R3) from screen with no referable DR.
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Fig. 2. Time to referable DR (RDR) from screen with no referable DR. [Correction added on
11 April after online publication to reﬂect the correct ﬁgure legend. It was previously reported
that the ﬁgure describes the time to proliferative DR (R3) from screen with no referable DR.]
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niﬁcantly higher for those with back-
ground DR in both eyes than those
with background DR in 1 eye only or
with no DR. This effect was seen in
all age groups. Reports from the
UKPDS (Kohner et al. 1999, 2001)
demonstrated that the number of mic-
roaneurysms had a high predictive
value for worsening retinopathy and
that there was a greater likelihood of
having laser treatment over the fol-
lowing 9 years if there were micro-
aneurysms in both eyes at baseline as
opposed to one eye alone. However,
involvement of a second eye with
background DR in this study does
appear to have a greater effect than
we had anticipated.
The cumulative 4-year risk of pro-
gression to proliferative DR is less
than one in 1000 for those with no
DR or in 1 eye only but was found in
one in 200 of those with background
DR in both eyes. Similarly, the cumu-
lative 4-year risk of development of
referable DR was 1 in 3 for those with
background DR in both eyes but less
than 1 in 10 and 1 in 20 in those with
only one or neither eye affected.
High-quality photographic screen-
ing and grading and diligent recording
of early lesions of retinopathy are
essential to enable classiﬁcation of
risk. This is only possible when the
photography and grading is carried
out in a quality assured environment
by well trained and motivated staff.
The results of this study may help
to design and power clinical trials test-
ing interventions such as new drug
treatments for diabetic retinopathy.
Many clinical trials require a two-step
progression per eye or three-step pro-
gression per patient on the ETDRS
severity scale (Chew 2001; ETDRS
1991). The majority of individual eyes
that have progressed from R1 mild
non-proliferative diabetic retinopathy
to R2 moderate to severe non-prolifer-
ative diabetic retinopathy in this study
will have progressed by the equivalent
of two steps and counting both eyes,
by the equivalent of three steps on the
ETDRS severity scale. If patients were
selected who had bilateral background
DR or mild NPDR, we have demon-
strated an overall progression to R2
or R3 of 15.9% after 4 years. A trial
of an intervention for diabetic retinop-
athy would beneﬁt from entry criteria
of background or mild non-prolifera-
tive diabetic retinopathy in two eyes.
The intervention is clearly more likely
to see an effect on two step progres-
sion than with entry criteria of back-
ground or mild non-proliferative
diabetic retinopathy in only one eye.
This would mean that a reduced sam-
ple size of patients would be needed
within the trial.
The latest ﬁgures from the Depart-
ment of Health (DH 2011) in England
show that in the last 12 months,
2.5 million people were identiﬁed with
diabetes, 2.3 million people were
offered screening and 1.8 million people
were actually screened. There is cur-
rently an epidemic of diabetes in the
world, and this is putting a strain on the
national screening services that are cur-
rently operating, and there is a strong
argument for optimizing screening
intervals based on individual risk. This
risk may be based on a previous screen-
ing result (Agardh & Tababat-Khani
2011; Chalk et al. 2012; Olafsdottir &
Stefansson 2007; Younis et al. 2003a,b)
or on the basis of previously deﬁned
individual risk factors (Mehlsen et al.
2011, 2012). The results of this study
provide background data on current
levels of risk based on one screening
result as compared to a recent study
(Stratton et al. 2012) in our unit based
on the results of two consecutive screen-
ing results. England, Scotland Wales
and Northern Ireland are currently
looking at the latest evidence of risk
based on what data is readily available
within the health information systems
of the four countries to develop a uni-
ﬁed approach to this optimization of
screening intervals.
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